Christopher Gignoux
Concepts (414)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 57 | 2026 | 1407 | 3.740 |
Why?
| | Genetics, Population | 34 | 2026 | 217 | 3.340 |
Why?
| | Polymorphism, Single Nucleotide | 68 | 2026 | 2158 | 2.550 |
Why?
| | Genomics | 22 | 2026 | 825 | 1.990 |
Why?
| | Genetic Predisposition to Disease | 35 | 2026 | 2378 | 1.910 |
Why?
| | Genome, Human | 25 | 2025 | 420 | 1.840 |
Why?
| | Multifactorial Inheritance | 17 | 2026 | 195 | 1.750 |
Why?
| | Genetic Variation | 18 | 2025 | 972 | 1.630 |
Why?
| | Models, Genetic | 14 | 2026 | 524 | 1.390 |
Why?
| | Asthma | 21 | 2026 | 1797 | 1.220 |
Why?
| | Precision Medicine | 5 | 2026 | 459 | 1.070 |
Why?
| | Transcriptome | 8 | 2026 | 1038 | 1.040 |
Why?
| | Biological Specimen Banks | 7 | 2026 | 109 | 1.010 |
Why?
| | Haplotypes | 23 | 2025 | 499 | 0.900 |
Why?
| | Genetics, Medical | 5 | 2023 | 23 | 0.860 |
Why?
| | Genotype | 26 | 2026 | 1852 | 0.760 |
Why?
| | Gene Frequency | 14 | 2026 | 487 | 0.760 |
Why?
| | Pharmacogenetics | 2 | 2021 | 175 | 0.730 |
Why?
| | Gastritis | 1 | 2023 | 116 | 0.700 |
Why?
| | Enteritis | 1 | 2023 | 104 | 0.700 |
Why?
| | Humans | 148 | 2026 | 145474 | 0.670 |
Why?
| | Thyroid Neoplasms | 4 | 2026 | 350 | 0.670 |
Why?
| | Software | 5 | 2026 | 680 | 0.660 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.660 |
Why?
| | Receptors, KIR | 6 | 2026 | 118 | 0.620 |
Why?
| | Human Migration | 6 | 2021 | 25 | 0.600 |
Why?
| | Quantitative Trait Loci | 8 | 2026 | 378 | 0.570 |
Why?
| | Gene Flow | 8 | 2020 | 87 | 0.570 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2018 | 8 | 0.570 |
Why?
| | Smad2 Protein | 1 | 2018 | 37 | 0.560 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 331 | 0.560 |
Why?
| | Phenotype | 17 | 2026 | 3155 | 0.520 |
Why?
| | Pedigree | 4 | 2025 | 515 | 0.520 |
Why?
| | Gene Expression Profiling | 7 | 2026 | 1767 | 0.460 |
Why?
| | Chromosome Mapping | 11 | 2023 | 506 | 0.460 |
Why?
| | DNA Methylation | 5 | 2025 | 674 | 0.450 |
Why?
| | Population | 2 | 2014 | 30 | 0.440 |
Why?
| | DNA, Mitochondrial | 6 | 2016 | 211 | 0.430 |
Why?
| | Population Growth | 2 | 2012 | 12 | 0.430 |
Why?
| | Metagenomics | 4 | 2023 | 149 | 0.430 |
Why?
| | Indians, North American | 7 | 2021 | 597 | 0.420 |
Why?
| | Obesity | 5 | 2025 | 3116 | 0.400 |
Why?
| | Mexican Americans | 7 | 2023 | 119 | 0.390 |
Why?
| | Evolution, Molecular | 6 | 2021 | 492 | 0.380 |
Why?
| | Agriculture | 2 | 2011 | 94 | 0.380 |
Why?
| | Alleles | 13 | 2026 | 894 | 0.370 |
Why?
| | Genetic Loci | 7 | 2019 | 264 | 0.350 |
Why?
| | Exome | 5 | 2022 | 227 | 0.350 |
Why?
| | Female | 59 | 2026 | 78844 | 0.340 |
Why?
| | Molecular Epidemiology | 3 | 2023 | 73 | 0.320 |
Why?
| | Indians, South American | 2 | 2020 | 23 | 0.320 |
Why?
| | Atherosclerosis | 2 | 2026 | 409 | 0.310 |
Why?
| | Case-Control Studies | 14 | 2026 | 3623 | 0.310 |
Why?
| | Nasal Mucosa | 2 | 2025 | 112 | 0.310 |
Why?
| | Genetic Association Studies | 3 | 2022 | 369 | 0.300 |
Why?
| | Male | 55 | 2026 | 72842 | 0.300 |
Why?
| | Population Groups | 2 | 2020 | 56 | 0.300 |
Why?
| | Computational Biology | 3 | 2023 | 669 | 0.290 |
Why?
| | Epigenesis, Genetic | 5 | 2025 | 679 | 0.290 |
Why?
| | Linkage Disequilibrium | 9 | 2023 | 253 | 0.290 |
Why?
| | Gene Expression Regulation | 3 | 2026 | 2597 | 0.270 |
Why?
| | Proteome | 2 | 2024 | 514 | 0.270 |
Why?
| | Skin Pigmentation | 2 | 2018 | 48 | 0.270 |
Why?
| | Kidney Diseases | 2 | 2025 | 425 | 0.270 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2187 | 0.260 |
Why?
| | Genetic Heterogeneity | 2 | 2026 | 66 | 0.260 |
Why?
| | Risk Factors | 19 | 2025 | 10885 | 0.260 |
Why?
| | Selection, Genetic | 4 | 2019 | 261 | 0.260 |
Why?
| | Killer Cells, Natural | 5 | 2026 | 480 | 0.250 |
Why?
| | Receptors, KIR2DL1 | 2 | 2018 | 22 | 0.250 |
Why?
| | Gene-Environment Interaction | 3 | 2023 | 180 | 0.250 |
Why?
| | Genetic Markers | 7 | 2023 | 335 | 0.250 |
Why?
| | Mexico | 8 | 2023 | 233 | 0.240 |
Why?
| | Colorectal Neoplasms | 2 | 2025 | 866 | 0.240 |
Why?
| | Phylogeography | 5 | 2020 | 50 | 0.240 |
Why?
| | Environmental Exposure | 3 | 2017 | 578 | 0.240 |
Why?
| | Data Compression | 1 | 2026 | 8 | 0.240 |
Why?
| | Body Mass Index | 5 | 2025 | 2445 | 0.230 |
Why?
| | Colorado | 4 | 2024 | 4553 | 0.230 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2025 | 14 | 0.230 |
Why?
| | Thyroid Diseases | 1 | 2026 | 44 | 0.230 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2025 | 16 | 0.230 |
Why?
| | Minority Groups | 2 | 2019 | 284 | 0.230 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2025 | 2588 | 0.230 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2025 | 40 | 0.220 |
Why?
| | Delivery of Health Care | 2 | 2023 | 946 | 0.220 |
Why?
| | Phylogeny | 7 | 2022 | 917 | 0.220 |
Why?
| | Algorithms | 4 | 2025 | 1845 | 0.210 |
Why?
| | RNA Splicing | 1 | 2026 | 284 | 0.210 |
Why?
| | Puerto Rico | 8 | 2021 | 62 | 0.210 |
Why?
| | Computer Simulation | 7 | 2026 | 1003 | 0.210 |
Why?
| | Bivalvia | 1 | 2024 | 6 | 0.210 |
Why?
| | Heterozygote | 3 | 2021 | 313 | 0.200 |
Why?
| | Chromosomes, Human, Pair 6 | 3 | 2014 | 46 | 0.200 |
Why?
| | Genes, MHC Class I | 2 | 2021 | 37 | 0.200 |
Why?
| | Longevity | 1 | 2025 | 178 | 0.200 |
Why?
| | Aged | 16 | 2025 | 26153 | 0.200 |
Why?
| | Triglycerides | 3 | 2025 | 520 | 0.200 |
Why?
| | Thyroid Nodule | 1 | 2024 | 57 | 0.190 |
Why?
| | Long QT Syndrome | 1 | 2024 | 68 | 0.190 |
Why?
| | United Kingdom | 4 | 2026 | 344 | 0.190 |
Why?
| | Young Adult | 12 | 2022 | 14218 | 0.190 |
Why?
| | Aortic Valve Stenosis | 1 | 2025 | 256 | 0.180 |
Why?
| | Glaucoma, Open-Angle | 1 | 2024 | 104 | 0.180 |
Why?
| | Proteins | 2 | 2022 | 1023 | 0.180 |
Why?
| | Receptors, KIR3DS1 | 1 | 2022 | 7 | 0.180 |
Why?
| | Receptors, KIR3DL1 | 1 | 2022 | 20 | 0.180 |
Why?
| | Immunoglobulin E | 2 | 2014 | 315 | 0.180 |
Why?
| | C-Reactive Protein | 1 | 2024 | 422 | 0.170 |
Why?
| | Demography | 5 | 2018 | 282 | 0.170 |
Why?
| | Middle Aged | 19 | 2025 | 36215 | 0.170 |
Why?
| | Emigration and Immigration | 3 | 2013 | 66 | 0.170 |
Why?
| | Myocardial Ischemia | 1 | 2023 | 285 | 0.170 |
Why?
| | Collagen Type VII | 1 | 2021 | 27 | 0.170 |
Why?
| | Jews | 1 | 2021 | 20 | 0.170 |
Why?
| | Obesity, Morbid | 1 | 2025 | 293 | 0.170 |
Why?
| | Epidermolysis Bullosa Dystrophica | 1 | 2021 | 41 | 0.170 |
Why?
| | Pharmacogenomic Variants | 1 | 2021 | 35 | 0.170 |
Why?
| | History, Medieval | 3 | 2021 | 46 | 0.170 |
Why?
| | Uterine Hemorrhage | 1 | 2021 | 41 | 0.160 |
Why?
| | Interleukin-6 | 1 | 2025 | 776 | 0.160 |
Why?
| | Drug Implants | 1 | 2021 | 83 | 0.160 |
Why?
| | Electrocardiography | 1 | 2024 | 665 | 0.160 |
Why?
| | Adult | 20 | 2025 | 40777 | 0.160 |
Why?
| | Indians, Central American | 1 | 2020 | 6 | 0.160 |
Why?
| | Eosinophilia | 1 | 2023 | 223 | 0.160 |
Why?
| | Adiposity | 1 | 2025 | 532 | 0.160 |
Why?
| | Lipids | 1 | 2025 | 707 | 0.160 |
Why?
| | Population Health | 1 | 2021 | 44 | 0.160 |
Why?
| | CpG Islands | 3 | 2025 | 163 | 0.160 |
Why?
| | Latin America | 2 | 2018 | 96 | 0.160 |
Why?
| | Reference Standards | 1 | 2020 | 177 | 0.150 |
Why?
| | Adaptation, Biological | 1 | 2020 | 48 | 0.150 |
Why?
| | Adolescent | 18 | 2021 | 22529 | 0.150 |
Why?
| | Self Report | 2 | 2021 | 870 | 0.150 |
Why?
| | Pre-Eclampsia | 1 | 2022 | 206 | 0.150 |
Why?
| | Principal Component Analysis | 2 | 2026 | 193 | 0.150 |
Why?
| | Lipase | 1 | 2020 | 75 | 0.150 |
Why?
| | Human Genetics | 1 | 2019 | 3 | 0.150 |
Why?
| | Data Interpretation, Statistical | 1 | 2021 | 368 | 0.150 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2023 | 364 | 0.140 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2017 | 749 | 0.140 |
Why?
| | Apolipoprotein L1 | 1 | 2018 | 14 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2025 | 1140 | 0.140 |
Why?
| | Geographic Mapping | 1 | 2019 | 26 | 0.140 |
Why?
| | United States | 16 | 2025 | 16098 | 0.140 |
Why?
| | Antiporters | 1 | 2018 | 22 | 0.140 |
Why?
| | Europe | 5 | 2020 | 418 | 0.140 |
Why?
| | Coronary Artery Disease | 2 | 2023 | 749 | 0.140 |
Why?
| | Liver Diseases | 1 | 2021 | 305 | 0.140 |
Why?
| | Primates | 1 | 2019 | 133 | 0.130 |
Why?
| | HLA-C Antigens | 1 | 2018 | 37 | 0.130 |
Why?
| | Chromosomes, Human, Y | 2 | 2008 | 37 | 0.130 |
Why?
| | Microbiota | 2 | 2023 | 730 | 0.130 |
Why?
| | Dermatitis, Atopic | 1 | 2021 | 322 | 0.130 |
Why?
| | Collagen Diseases | 1 | 2017 | 8 | 0.130 |
Why?
| | Fibrillar Collagens | 1 | 2017 | 14 | 0.130 |
Why?
| | Databases, Genetic | 3 | 2026 | 238 | 0.130 |
Why?
| | Epistasis, Genetic | 1 | 2017 | 63 | 0.130 |
Why?
| | Apolipoprotein A-V | 1 | 2017 | 4 | 0.130 |
Why?
| | Gene Pool | 2 | 2013 | 4 | 0.130 |
Why?
| | Weight Gain | 1 | 2021 | 561 | 0.130 |
Why?
| | History, Ancient | 3 | 2013 | 53 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1497 | 0.120 |
Why?
| | Women's Health | 1 | 2019 | 314 | 0.120 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 265 | 0.120 |
Why?
| | Saliva | 2 | 2020 | 246 | 0.120 |
Why?
| | Inflammation | 2 | 2025 | 2878 | 0.120 |
Why?
| | Homozygote | 3 | 2023 | 199 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2021 | 1111 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 881 | 0.120 |
Why?
| | Language | 2 | 2011 | 323 | 0.120 |
Why?
| | Machine Learning | 3 | 2026 | 587 | 0.110 |
Why?
| | Research Design | 1 | 2022 | 1137 | 0.110 |
Why?
| | Colombia | 3 | 2021 | 42 | 0.110 |
Why?
| | Cohort Studies | 6 | 2026 | 6013 | 0.110 |
Why?
| | Social Class | 2 | 2013 | 264 | 0.110 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5904 | 0.100 |
Why?
| | Genealogy and Heraldry | 1 | 2013 | 3 | 0.100 |
Why?
| | Africa, Southern | 3 | 2018 | 6 | 0.100 |
Why?
| | Minority Health | 1 | 2013 | 18 | 0.100 |
Why?
| | Health Surveys | 1 | 2016 | 518 | 0.100 |
Why?
| | Ikaros Transcription Factor | 1 | 2014 | 23 | 0.100 |
Why?
| | Population Dynamics | 2 | 2012 | 142 | 0.100 |
Why?
| | Premature Birth | 1 | 2018 | 388 | 0.100 |
Why?
| | Urban Health | 1 | 2013 | 96 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1707 | 0.100 |
Why?
| | Search Engine | 1 | 2013 | 13 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2020 | 1164 | 0.100 |
Why?
| | Kv Channel-Interacting Proteins | 1 | 2013 | 2 | 0.100 |
Why?
| | Albuterol | 1 | 2013 | 76 | 0.100 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 41 | 0.100 |
Why?
| | Emigrants and Immigrants | 1 | 2016 | 157 | 0.100 |
Why?
| | Neanderthals | 1 | 2013 | 13 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 447 | 0.100 |
Why?
| | Forced Expiratory Volume | 2 | 2013 | 450 | 0.090 |
Why?
| | Child | 15 | 2020 | 22707 | 0.090 |
Why?
| | Carrier Proteins | 1 | 2017 | 728 | 0.090 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2012 | 27 | 0.090 |
Why?
| | Kallikreins | 1 | 2012 | 26 | 0.090 |
Why?
| | HLA-DQ beta-Chains | 1 | 2012 | 58 | 0.090 |
Why?
| | Mutation | 5 | 2018 | 4075 | 0.090 |
Why?
| | Air Pollution | 1 | 2016 | 314 | 0.090 |
Why?
| | Bronchodilator Agents | 1 | 2013 | 187 | 0.090 |
Why?
| | Biological Evolution | 2 | 2019 | 467 | 0.090 |
Why?
| | Respiratory Function Tests | 2 | 2012 | 544 | 0.090 |
Why?
| | Prostate-Specific Antigen | 1 | 2012 | 161 | 0.090 |
Why?
| | HLA-B Antigens | 2 | 2022 | 58 | 0.090 |
Why?
| | History, 17th Century | 1 | 2011 | 14 | 0.080 |
Why?
| | History, 15th Century | 1 | 2011 | 11 | 0.080 |
Why?
| | History, 18th Century | 1 | 2011 | 18 | 0.080 |
Why?
| | Polynesia | 2 | 2021 | 3 | 0.080 |
Why?
| | Tuberculosis | 1 | 2014 | 283 | 0.080 |
Why?
| | Mycobacterium tuberculosis | 1 | 2014 | 318 | 0.080 |
Why?
| | Cluster Analysis | 3 | 2023 | 500 | 0.080 |
Why?
| | History, 19th Century | 1 | 2011 | 63 | 0.080 |
Why?
| | Anthropometry | 2 | 2025 | 206 | 0.080 |
Why?
| | Respiratory Sounds | 1 | 2011 | 103 | 0.080 |
Why?
| | Chile | 2 | 2021 | 27 | 0.080 |
Why?
| | Lung | 2 | 2016 | 4106 | 0.080 |
Why?
| | Estrogen Receptor alpha | 1 | 2012 | 151 | 0.080 |
Why?
| | Body Height | 2 | 2023 | 202 | 0.080 |
Why?
| | Breast Neoplasms | 2 | 2014 | 2382 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2011 | 267 | 0.080 |
Why?
| | History, 21st Century | 1 | 2011 | 222 | 0.080 |
Why?
| | HLA Antigens | 2 | 2026 | 240 | 0.080 |
Why?
| | History, 20th Century | 1 | 2011 | 328 | 0.080 |
Why?
| | Genotyping Techniques | 2 | 2020 | 71 | 0.070 |
Why?
| | South Africa | 3 | 2015 | 266 | 0.070 |
Why?
| | Peru | 2 | 2022 | 60 | 0.070 |
Why?
| | Vital Capacity | 1 | 2010 | 292 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1443 | 0.070 |
Why?
| | Electronic Health Records | 3 | 2021 | 1196 | 0.070 |
Why?
| | Chromosomes, Human, Pair 8 | 2 | 2019 | 38 | 0.070 |
Why?
| | Africa | 3 | 2017 | 119 | 0.070 |
Why?
| | South America | 2 | 2020 | 56 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 919 | 0.070 |
Why?
| | Americas | 2 | 2018 | 27 | 0.070 |
Why?
| | Life Style | 2 | 2022 | 485 | 0.070 |
Why?
| | Signal Transduction | 2 | 2019 | 5216 | 0.070 |
Why?
| | Risk | 3 | 2018 | 919 | 0.070 |
Why?
| | Ants | 1 | 2007 | 25 | 0.070 |
Why?
| | Linguistics | 1 | 2007 | 26 | 0.060 |
Why?
| | Bayes Theorem | 2 | 2024 | 420 | 0.060 |
Why?
| | Odds Ratio | 3 | 2014 | 1082 | 0.060 |
Why?
| | Whole Genome Sequencing | 2 | 2018 | 177 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 2 | 2019 | 54 | 0.060 |
Why?
| | Speech | 1 | 2007 | 76 | 0.060 |
Why?
| | Human Genome Project | 2 | 2017 | 15 | 0.060 |
Why?
| | Organ Specificity | 1 | 2026 | 309 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2025 | 41 | 0.060 |
Why?
| | Mendelian Randomization Analysis | 1 | 2025 | 55 | 0.060 |
Why?
| | Cytokine Receptor gp130 | 1 | 2025 | 11 | 0.060 |
Why?
| | Lung Diseases | 1 | 2012 | 780 | 0.060 |
Why?
| | Bias | 2 | 2019 | 197 | 0.060 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 530 | 0.060 |
Why?
| | Receptors, Interleukin-6 | 1 | 2025 | 48 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3922 | 0.050 |
Why?
| | Base Sequence | 3 | 2016 | 2170 | 0.050 |
Why?
| | RNA | 1 | 2011 | 910 | 0.050 |
Why?
| | Body Size | 1 | 2025 | 88 | 0.050 |
Why?
| | Phenethylamines | 1 | 2024 | 16 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2025 | 165 | 0.050 |
Why?
| | Torsades de Pointes | 1 | 2024 | 23 | 0.050 |
Why?
| | Argentina | 2 | 2015 | 30 | 0.050 |
Why?
| | Child, Preschool | 6 | 2020 | 11853 | 0.050 |
Why?
| | Microsatellite Repeats | 3 | 2011 | 157 | 0.050 |
Why?
| | Polymorphism, Genetic | 2 | 2018 | 614 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2026 | 442 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 617 | 0.050 |
Why?
| | Iran | 1 | 2023 | 44 | 0.050 |
Why?
| | Geography | 2 | 2016 | 187 | 0.050 |
Why?
| | Prevalence | 2 | 2025 | 2865 | 0.050 |
Why?
| | Los Angeles | 1 | 2023 | 73 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2026 | 574 | 0.050 |
Why?
| | Biology | 1 | 2024 | 88 | 0.050 |
Why?
| | Caribbean Region | 2 | 2013 | 29 | 0.050 |
Why?
| | Minisatellite Repeats | 1 | 2002 | 36 | 0.050 |
Why?
| | Lipoprotein(a) | 1 | 2023 | 69 | 0.050 |
Why?
| | Factor X | 1 | 2022 | 26 | 0.050 |
Why?
| | Factor VII | 1 | 2022 | 24 | 0.050 |
Why?
| | Genes | 1 | 2002 | 227 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2025 | 317 | 0.050 |
Why?
| | Age Factors | 2 | 2020 | 3342 | 0.040 |
Why?
| | Epigenomics | 1 | 2022 | 114 | 0.040 |
Why?
| | Blood Coagulation Factors | 1 | 2022 | 71 | 0.040 |
Why?
| | Genes, Recessive | 1 | 2021 | 78 | 0.040 |
Why?
| | Inheritance Patterns | 1 | 2021 | 45 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 2021 | 52 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2021 | 45 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2024 | 456 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 161 | 0.040 |
Why?
| | Bronchi | 2 | 2014 | 263 | 0.040 |
Why?
| | Genome, Viral | 1 | 2022 | 214 | 0.040 |
Why?
| | Infant, Newborn | 3 | 2020 | 6447 | 0.040 |
Why?
| | Central America | 1 | 2020 | 28 | 0.040 |
Why?
| | Models, Statistical | 1 | 2025 | 671 | 0.040 |
Why?
| | China | 1 | 2021 | 270 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 239 | 0.040 |
Why?
| | Phospholipases A2, Calcium-Independent | 1 | 2020 | 18 | 0.040 |
Why?
| | Sulfonamides | 1 | 2024 | 583 | 0.040 |
Why?
| | Acyltransferases | 1 | 2020 | 78 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 785 | 0.040 |
Why?
| | Infant | 3 | 2021 | 10077 | 0.040 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2019 | 21 | 0.040 |
Why?
| | Topography, Medical | 1 | 2019 | 10 | 0.040 |
Why?
| | Asia, Northern | 1 | 2018 | 1 | 0.040 |
Why?
| | Mongolia | 1 | 2018 | 6 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1997 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2020 | 2953 | 0.040 |
Why?
| | Classification | 1 | 2019 | 43 | 0.040 |
Why?
| | Databases, Nucleic Acid | 1 | 2018 | 38 | 0.040 |
Why?
| | Animals | 6 | 2024 | 38030 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2019 | 63 | 0.030 |
Why?
| | Receptors, Natural Killer Cell | 1 | 2018 | 16 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2019 | 145 | 0.030 |
Why?
| | Hominidae | 1 | 2019 | 87 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2020 | 8333 | 0.030 |
Why?
| | Altitude | 1 | 2022 | 463 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2018 | 80 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 563 | 0.030 |
Why?
| | New York City | 1 | 2017 | 84 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 969 | 0.030 |
Why?
| | DNA | 1 | 2024 | 1435 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3413 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1149 | 0.030 |
Why?
| | Multigene Family | 1 | 2017 | 210 | 0.030 |
Why?
| | DNA, Intergenic | 1 | 2016 | 26 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2014 | 2883 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 133 | 0.030 |
Why?
| | Parents | 1 | 2025 | 1403 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2024 | 2507 | 0.030 |
Why?
| | Musculoskeletal Diseases | 1 | 2017 | 90 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2019 | 375 | 0.030 |
Why?
| | Prospective Studies | 3 | 2014 | 8057 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1891 | 0.030 |
Why?
| | Ligands | 1 | 2018 | 665 | 0.030 |
Why?
| | Sexism | 1 | 2016 | 68 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2019 | 321 | 0.030 |
Why?
| | Protein Conformation | 1 | 2019 | 938 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 2017 | 154 | 0.030 |
Why?
| | Risk Assessment | 1 | 2025 | 3747 | 0.030 |
Why?
| | Genetic Testing | 1 | 2018 | 480 | 0.030 |
Why?
| | Placenta | 1 | 2022 | 786 | 0.030 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2014 | 17 | 0.030 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2014 | 23 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2019 | 2129 | 0.030 |
Why?
| | Crosses, Genetic | 1 | 2014 | 123 | 0.030 |
Why?
| | San Francisco | 1 | 2013 | 60 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 86 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 632 | 0.030 |
Why?
| | HapMap Project | 1 | 2013 | 4 | 0.020 |
Why?
| | Models, Molecular | 1 | 2019 | 1598 | 0.020 |
Why?
| | Biomarkers | 1 | 2025 | 4295 | 0.020 |
Why?
| | Africa, Northern | 1 | 2013 | 4 | 0.020 |
Why?
| | Mammography | 1 | 2014 | 166 | 0.020 |
Why?
| | Blood Glucose | 1 | 2023 | 2341 | 0.020 |
Why?
| | Sex Factors | 1 | 2019 | 2105 | 0.020 |
Why?
| | Databases, Factual | 1 | 2019 | 1490 | 0.020 |
Why?
| | Interleukin-13 | 1 | 2014 | 146 | 0.020 |
Why?
| | Skin Tests | 1 | 2013 | 94 | 0.020 |
Why?
| | Th2 Cells | 1 | 2014 | 175 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 506 | 0.020 |
Why?
| | Hawaii | 1 | 2012 | 37 | 0.020 |
Why?
| | Genome, Mitochondrial | 1 | 2012 | 26 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2238 | 0.020 |
Why?
| | Income | 1 | 2013 | 202 | 0.020 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2012 | 59 | 0.020 |
Why?
| | Air Pollutants | 1 | 2016 | 405 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 171 | 0.020 |
Why?
| | Receptors, Estrogen | 1 | 2014 | 401 | 0.020 |
Why?
| | Markov Chains | 1 | 2012 | 132 | 0.020 |
Why?
| | Boston | 1 | 2011 | 93 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 407 | 0.020 |
Why?
| | Educational Status | 1 | 2013 | 466 | 0.020 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2011 | 23 | 0.020 |
Why?
| | Angola | 1 | 2011 | 1 | 0.020 |
Why?
| | Canada | 1 | 2012 | 431 | 0.020 |
Why?
| | Mozambique | 1 | 2011 | 7 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2012 | 135 | 0.020 |
Why?
| | Africa South of the Sahara | 1 | 2011 | 54 | 0.020 |
Why?
| | Insurance, Health | 1 | 2013 | 310 | 0.020 |
Why?
| | North America | 1 | 2011 | 302 | 0.020 |
Why?
| | Culture | 1 | 2011 | 124 | 0.020 |
Why?
| | Allergens | 1 | 2013 | 386 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 283 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 428 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2011 | 199 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 7123 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7202 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 798 | 0.020 |
Why?
| | Hypersensitivity | 1 | 2011 | 254 | 0.020 |
Why?
| | Tanzania | 1 | 2008 | 72 | 0.020 |
Why?
| | Social Behavior | 1 | 2011 | 284 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 2134 | 0.020 |
Why?
| | Family | 1 | 2013 | 682 | 0.020 |
Why?
| | Inbreeding | 1 | 2007 | 20 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 845 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1321 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1480 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3542 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1734 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 592 | 0.010 |
Why?
| | Reproduction | 1 | 2007 | 208 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1764 | 0.010 |
Why?
| | Smoking | 1 | 2012 | 1472 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2930 | 0.010 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2002 | 28 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2002 | 40 | 0.010 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2002 | 39 | 0.010 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2002 | 48 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 333 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 6066 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18329 | 0.010 |
Why?
|
|
Gignoux's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|